Clinical Trial Update: Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy [Phase 1]

View source ↗

Summary

This Phase 1 trial reports safety data for low-dose tamoxifen in patients with chronic hepatitis C who failed standard therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Tamoxifen (tamoxifen)

Snippet

Sponsor: Bader, Ted, M.D. | Conditions: Chronic Hepatitis C | Phase 1 | Status: COMPLETED